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Abstract Porphyromonas gingivalis is a leading pathogen in
chronic periodontitis, a disease process involving progressive
destruction of the tissues that support the teeth. Recently, the
organism has been reported to produce a unique bacterial
enzyme, P. gingivalis peptidyl-arginine deiminase (PPAD),
which has the ability to convert arginine residues in proteins
to citrulline. Protein citrullination alters protein structure and
function; hence, PPADmay be involved in deregulation of the
host’s signalling network and immune evasion. Further, accu-
mulating evidence suggests a role for autoimmunity against
citrullinated proteins in the development of rheumatoid arthri-
tis (RA). As inflammatory conditions in the lungs of cigarette
smokers contribute to the breakdown of immune tolerance to
citrullinated epitopes, chronic exposure to citrullinated pro-
teins at periodontitis sites may also predispose susceptible
individuals to the development of autoantibodies and the
initiation of RA. In this review, we discuss evidence that
PPADmay represent a mechanistic link between periodontitis
and RA, diseases that are known to be significantly associated
at the epidemiological level.
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Introduction
Rheumatoid arthritis (RA) and periodontal disease (PD) are
two common chronic inflammatory diseases affecting humans
worldwide. In 2003, the total cost attributable to arthritis and
other rheumatic conditions in the United States was $128
billion, equivalent to 1.2 % of the 2003 U.S. gross domestic
product (http://www.cdc.gov/arthritis/data_statistics).
Furthermore, 23 % of the US population age 65+ has been
reported to suffer from severe PD. Together, development of
both diseases brings considerable consequences for public
health and for the quality of life of affected individuals.
There may be a non-causal association between PD and
RA due to shared genetic and environmental risk factors, such
as expression of the MHC class II HLA-DRB1 allele and
smoking, respectively [1–5]. Despite differences in initiating
etiological mechanisms, evidence emerging from numerous
clinical and epidemiological studies suggests an association
between RA and PD [6–9]. Compared to the general popula-
tion, subjects with PD are at an increased risk of developing
RA, and vice versa; PD is at least 2-fold more prevalent in
patients with RA. In addition, the clinical course of PD in RA
patients is more severe and is independent of age, gender,
ethnicity, or smoking history, as compared to non-RA indi-
viduals. Furthermore, RA and PD utilise similar effector de-
structive mechanisms, in that the inflammatory cells and pro-
inflammatory cytokines that drive chronic bone erosion in RA
and chronic gum destruction in PD are similar. Current novel
and exciting findings strongly support the idea that PD could
be a factor in the initiation and maintenance of the autoim-
mune inflammatory responses that occur in RA [10].
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Porphyromonas gingivalis is a Key Pathogen
in Periodontitis
Periodontitis, the chronic inflammation of the supporting tis-
sues surrounding the teeth, is one of the most prevalent
inflammatory diseases of mankind. Tooth loss is common in
severe forms of the disease and has been reported to afflict
more than 20 % of the human population [11]. Further, a
paradigm is emerging linking periodontitis with the develop-
ment of atherosclerosis [12] and RA [7, 9, 13, 14].
It is now generally accepted that chronic periodontitis is
initiated by the colonisation of dental plaque by a set of path-
ogenic bacteria, especially P. gingivalis, Tannerella forsythia,
and Treponema denticola. These periodontal pathogens, re-
ferred to as the “red complex” due to their strong association
with the disease [15], are well equipped with a broad array of
virulence factors. P. gingivalis expresses lipopolysaccharide
(LPS), fimbrae, and haemagglutins, which enable the bacteri-
um to colonise and invade periodontal pockets, and is therefore
known as the “master manipulator” of the host homeostatic
system [16]. Its most potent weapons are, however, extracellu-
lar cysteine proteases, referred to as gingipains, which allow the
bacterium to use the host innate immune response to its own
benefit [17, 18]. Because its gingipains render it resistant to
complement, P.gingivalis directly benefits from activation of
the complement pathway, which initiates and maintains the
inflammatory reaction [19]. In addition, degradation of antimi-
crobial peptides by gingipains allows other pathogenic bacteria
co-aggregating with P. gingivalis to persist in the gingiva.
Moreover, gingipains affect proinflammatory signalling path-
ways by cleavage and activation of the proteinase-activated
receptor-2 (PAR-2) on human neutrophils. Futile attempts by
the host immune response to eliminate infection subsequently
lead to connective tissue damage, including alveolar bone
resorption [20, 21].
Role of Citrullination in RA Development
It is now clear that the majority of RA cases are triggered by an
autoimmune response to citrullinated proteins. Such proteins are
generated under physiological conditions, but the loss of toler-
ance in genetically susceptible individuals initiates the generation
of autoantibodies against citrullinated proteins (ACPA) in the
synovia and the subsequent development of RA [22–24].
Protein citrullination by enzymatic deimination of the gua-
nidine group of an arginine side chain is the post-translational
modification that converts positively charged peptidyl-
arginine to neutral peptidyl citrulline. Protein citrullination is
essential for many physiological processes, including terminal
differentiation of the epidermis (pro-filaggrin and keratin),
brain development [myelin basic protein (MBP)], and regula-
tion of gene expression via chromatin remodeling [25, 26].
Apart from being involved in many physiological processes,
citrullination also occurs under the pathological inflammatory
conditions of excessive cellular apoptosis, necrosis, and
netosis. In the latter process, hypercitrullination of histones
is needed for formation of neutrophil extracellular traps,
which are part of the innate immune system response to
bacterial infection [26]. Thus, deimination has been linked to
multiple sclerosis, psoriasis, Alzheimer’s disease, primary
open-angle glaucoma, obstructive nephropathy, and RA.
The citrullination process leads to alterations in intra- and
inter-molecular interactions of protein targets possessing Arg
residues essential for their structure. This may alter the three-
dimensional architecture of modified proteins and their solu-
bility in water, and may lead to the generation of neo-epitopes,
thus breaching immunological tolerance to citrullinated pro-
teins. In susceptible individuals, the process may initiate a
cascade of events leading to the induction of RA [22, 23, 27].
Antibodies to ACPA are known to be a sensitive and specific
marker that can be detected years before the clinical onset of
the disease. During the clinical course of RA, their presence
and serum levels strongly correlate with disease severity. A
recent report reveals elevated levels of ACPA in patients with
aggressive periodontitis [28]. Furthermore, RA patients diag-
nosed as ACPA-positive were more likely to have moderate to
severe periodontitis than ACPA-negative RA patients [29].
Because the ACPA response is peptidyl citrulline-specific,
host enzymes which catalyse the protein modifications that
lead to the generation of citrullinated epitopes are considered
highly important targets for drug development.
PPAD is a Unique Bacterial Enzyme
among Peptidyl-arginine Deiminases
Protein citrullination is carried out by peptidyl-arginine
deiminases (PADs; enzyme commission number (EC)
3.5.3.15). The activity of mammalian PAD enzymes is depen-
dent on high concentrations of calcium (Ca2+); thus,
citrullination is likely to occur in conditions that lead to the
mobilisation of free intracellular calcium, such as chemokine
receptor ligation, cell death, and differentiation. Five different
PADs (PAD1, 2, 3, 4, and 6) identified in humans are encoded
by five paralogous genes clustered on chromosome 1p35–36.
PAD1 and PAD3 are mainly found in epidermis and hair folli-
cles; PAD2 is expressed in a variety of tissues, includingmuscle,
brain, and haematopoietic cells; and human PAD4 (formerly
known as PAD5) is found primarily in haematopoietic cells.
PAD homologues for some or all of these enzymes have also
been found in other mammals, with similar genomic organisa-
tion across species [30].
P. gingivalis is unique among periodontal pathogens in its
expression of peptidyl-arginine deiminase (PPAD). Some en-
zymatic properties of PPAD differ significantly from those of
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the human PADs. Specifically, PPAD is active at a higher pH
and does not require calcium for activity. PPAD also
citrullinates C-terminal arginine residues and deiminates free
arginine, while mammalian PADs lack these activities [31].
The process of modification of C-terminal arginines is facili-
tated by colocalisation of PPAD in the outer membrane with
arginine-specific gingipains (RGPs), cysteine proteases of
P. gingivalis [32••]. Gingipains cleave protein chains, exposing
C-terminal arginines that are rapidly citrullinated by PPAD,
which generates polypeptides with citrullinated Arg located at
the C-terminus. Arg-gingipain-null mutants of P. gingivalisare
devoid of citrullination, confirming that the citrullination of
surface proteins is dependent on the activity of arginine
gingipain proteases. Furthermore, recent data revealed that
PPAD citrullinates peptides generated by the degradation of
fibrinogen and α-enolase by P. gingivalis gingipains [33].
Citrullination of fibrin and vimentin by PPAD was also de-
scribed. Citrullination of bradykinin, another PPAD substrate,
at the C-terminus [31] may interfere with kinin proinflamma-
tory activity. Finally, PPAD deiminates the C-terminal Arg in
epidermal growth factor, abrogating this cytokine’s biological
activity [34]. PPAD is clearly expressed in vivo and is immu-
nogenic in mice, as we were able to detect antibodies against
PPAD in animals inoculated with a wild-type strain of
P. gingivalis (W83) but not with the PPAD-null isogenic
mutant [35••].
Recent findings indicate that infection with P. gingivalis
precedes RA and that the bacterium is a likely factor in the
initiation and maintenance of the autoimmune inflammatory
responses that occur in this disease [10]. In this respect, the
presence of P. gingivalis-PAD (PPAD), an enzyme expressed
by P. gingivalisbut absent in other prokaryotes [36], may have
a profound impact on the development and progression of RA
via citrullination of proteins to generate neo-epitopes.
Citrullination by PPAD as a Putative Mechanistic Link
between PD and RA
P. gingivalis is the only known microorganism to produce
PAD, and in inflamed P. gingivalis-infested periodontitis sites,
PPAD may set in motion a chain of events that breaks
immunotolerance to citrullinated proteins and leads to the
development of RA. In line with this hypothesis, ACPA titres
in RA patients have been shown to correlate with the presence
of PD [29]. Moreover, Lappin et al. recently revealed that
ACPA titres are higher in patients with PD compared to
healthy donors [37•].
Host Epitopes Modified by PPAD
Aberrant citrullination has been observed in RA; however, it is
still unclear whether citrullination in RA creates novel
epitopes or uncovers cryptic ones in susceptible individuals.
Among the potential autoantigens in RA that are efficiently
citrullinated by human PADs are fibrinogen, enolase,
vimentin, and collagen II (CII) [38, 39, 40•]. PPAD localised
on the bacterial surface is perfectly positioned to citrullinate
host proteins interacting with P. gingivalis via bacterial
adhesins. In keeping with this hypothesis, P. gingivalis rapidly
generates fibrinogen-derived peptides with carboxy-terminal
citrulline residues [33]. A B cell-dominant epitope of α-
enolase termed citrullinated enolase peptide-1 (CEP-1) was
also identified as an autoantigen in RA. Recent data revealed
that enolase is a substrate for PPAD. Furthermore, CEP-1
shows 82 % sequence similarity with P. gingivalis α-enolase
[41]. Therefore, CEP-1 antibodies cross-react with the equiv-
alent epitope of P. gingivalis-derived enolase. An increased
level of antibodies specific for CEP-1 was detected in the
chamber fluid of mice infected with P. gingivalis [35••]. Final-
ly, pathological changes typical of arthritis were induced in
DR4-IE transgenic mice immunised with citrullinated human
and P. gingivalis α-enolase [40•].
PPAD Autocitrullination
P. gingivalis efficiently citrullinates its own proteins, and sub-
cellular fractionation revealed that the majority of such pro-
teins are associated with the periplasm, and with the outer and
inner membrane fractions [33]. Although PPAD preferentially
citrullinates C-terminal arginine residues, recent data revealed
a striking feature of PPAD: it undergoes autocitrullination [31,
42]. Mass spectrometry analysis revealed citrullination of 7
out of 18 arginines in the PPAD polypeptide chain, all of
which were internal [32••]. Therefore, PPAD as a citrullinated
bacterial protein itself constitutes a potent antigen that may
break the tolerance to citrullinated host proteins. This hypoth-
esis was recently supported by the identification of IgG spe-
cifically recognising citrullinated PPAD in sera from RA
patients. A P. gingivalis strain that expresses catalytically
inactive PPAD and is thus devoid of autocitrullination
(PPADC351A) did not induce an antibody response, confirming
a specific immune response to citrullinated PPAD [32••].
Moreover, the significantly elevated antibody response to
PPAD, but not RgpB, in sera from RA patients compared to
sera from control and PD patients indicates that PPAD could
be an antigen relevant to the pathogenesis of RA. The speci-
ficity of the immune response to citrullinated PPAD was
confirmed by the reactivity of RA sera to multiple synthetic
citrullinated peptides spanning the PPAD polypeptide chain.
This study revealed the presence of antibodies to 10 of the 13
tested citrullinated peptides, specifically in RA sera [32••].
Two PPAD peptides (CPP3 and CPP8) were reactive in 40 %
of RA samples, indicating their possible application for
screening for anti-PPAD antibodies in future epidemiological
studies. Taken together, the above observations may suggest
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that P. gingivalis infection can uniquely prime the immune
response in RA due to the appearance of autocitrullinated
PPAD. The poten t i a l pa thophys io log ic ro le of
autocitrullinated PPAD in RA opens up a novel area for future
investigations.
In Vivo Role of PPAD
In vivo studies have revealed a relationship between joint
disease and PD, as mice with pre-existing periodontitis devel-
oped more severe arthritis at a faster rate than control animals
[43, 44•]. Moreover, there is an increasing body of evidence
showing that the severity of periodontitis is related to the
progression of RA, and that the profile of oral microbiota in
patients with new-onset RA is extremely similar to that of
patients suffering from chronic RA [45, 46]. Lastly, using a
collagen-induced arthritis model (CIA), it was demonstrated
for the first time that infection with P. gingivalis not only
exacerbates CIA but also appears to play a role in sensitising
animals to early disease development [35••]. The arthritis that
occurred in mice infected with P. gingivaliswas characterised
by significantly greater bone and cartilage destruction in the
affected joints. These clinical signs of arthritis manifested
significantly earlier and were accompanied by a more severe
disease course than in non-infected animals. The early onset
and aggravated progression of CIA occurred only in animals
inoculated with viable P. gingivalis. Infection with
P. intermedia, another important pathogen associated with
PDs [15], had no effect on the course of CIA. Similar to
infection with P. intermedia, inoculation with either heat-
killed P. gingivalisor the purified cell membrane fraction from
the same organism had no effect on either the rate or the
severity of CIA. Taken together, these findings indicate the
requirement for live P. gingivalis, which releases bacterial
factors exerting a direct or indirect (via stimulation of host
systems) effect on the host that ultimately triggers an autoim-
mune reaction. This hypothesis also drew on recent findings in
which immunity to P. gingivalis, but not to P. intermedia (or
Fusobacterium nucleatum), was shown to be significantly
associated with the presence of RA-related autoantibodies in
individuals at risk for the disease [47•].
Recent data revealed that chronic P. gingivalisoral infection
prior to arthritis induction increases Th17 cell immune re-
sponses, including significant secretion of cytokines such as
IL-1β, IL-6, IL-22, tumor necrosis factor-α, transforming
growth factor-β, and IL-23. This observation suggests that
chronic oral infection may influence RA development mainly
through the activation of Th17-related pathways [48].
The induction of ACPA is dependent on deiminase activity;
thus, PAD expressed byP. gingivalis is a potential risk factor in
Fig. 1 A model of periodontitis-initiated pathogenesis of rheumatoid arthritis (RA) initiated by PPAD/PAD-catalysed modification of proteins in the
inflamed periodontal tissue and driven by autoimmunity against citrullinated epitopes joints. Figure was created using Servier Medical Art
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RA development. Recent data revealed that inoculation of
animals with an isogenic P. gingivalis-PAD knockout strain
(ΔPPAD) prior to immunisation with CII had no influence on
clinical CIA development or progression [35••]. Histological-
ly, ΔPPAD inoculation had no effect on the degree of syno-
vitis, erosions, or neutrophil influx into the joints, as compared
to CIA controls. This is in complete contrast to animals
infected with the live wild-type strain (W83), suggesting that
PPAD likely contributes significantly to the pathogenesis of
the disease.
The enzyme by itself is immunogenic in mice, as antibod-
ies against PPADwere detected in animals inoculated with the
wild-type strain, W83 [35••]. Moreover, as mentioned before,
the anti-PPAD antibody response is unique to RA patients,
suggesting that PPAD may constitute a neo-antigen in RA
[32••]. Nevertheless, it is unlikely that this response contrib-
utes to the aggravation of CIA by P. gingivalis because the
level of anti-PPAD antibodies was very low. By contrast, the
level of antibodies to citrullinated peptides (aCCP) and to
enolase-derived citrullinated epitope (CEP-1), both of which
are implicated in autoimmunity in RA, strongly increased in
CIA mice infected with wild-type P. gingivalis [35••]. Finally,
demonstrating the role of autoantibody production in the
pathophysiology of CIA, P. gingivalis infection increased the
serum levels of specific IgG against CII, in contrast to either
ΔPPAD or CIA control mice.
Collectively, aggravation of these RA-associated patholo-
gies is dependent on PPAD activity, which, either directly or
indirectly (via the enhancement of inflammatory reactions and
the release of host PADs), leads to the generation of
citrullinated neo-epitopes, thus stimulating autoantibody pro-
duction. In this context, one may hypothesise that pathological
citrullination of proteins in gingival tissues by PPAD, within a
chronic inflammatory environment in which the immune sys-
tem is stimulated by bacteria-derived danger signals such as
LPS, fimbriae, and peptidoglycan, breaks immune tolerance
to citrullinated proteins and peptides, priming autoimmunity
in a subset of patients with RA [36] (Fig. 1).
Notably, human PADs, PPAD, and citrullinated proteins
have been detected in the oral mucosa and periodontium [33].
Thus, in periodontitis, the orchestrated citrullination of host
and/or bacterial proteins in vivo could trigger a loss of toler-
ance to structurally similar host proteins, resulting in the
expression of ACPA.
Conclusions
Together, PD and RA are responsible for significant loss of
function and morbidity in a large percentage of the population
worldwide. Therefore, for many years, scientists have tried in
vain to find a mechanistic link between both diseases in the
hope of facilitating the development of a novel, effective
treatment for both diseases. Based on these latest discoveries,
we believe that PPAD could be a target for successful therapy
or prevention of these crippling diseases.
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